# The correct wording to use when making a bequest to Garvan



Your bequest will change the health of future generations



### Please take this to your Solicitor when the time is right.

According to your personal situation and preferences, the following wording should be used when making a bequest:

"I give to the Garvan Institute of Medical Research, ABN 62 330 391 937 free of all duties

- a) All of my residuary estate (OR)
- b) \_\_\_\_\_ percentage of my residuary estate (OR)
- c) The sum of \$ \_\_\_\_\_(OR)
- d) [List asset or assets]

to be applied for the purposes of medical research by the Institute OR for the purpose of \_\_\_\_\_\_ [specify research area of your choice]. I declare that the receipt of a Director of the Institute or other authorised officer will be a sufficient discharge to my executors who will not be bound to see to the application of this gift."

If you need help with any aspect of making your bequest or you would like our Bequest Manager, Donna Mason, to talk to your solicitor please feel free to give her a call on (02) 9295 8559 or email d.mason@garvan.org.au.

If you choose to leave a bequest to Garvan we'd be very grateful if you could let us know as we'd welcome the opportunity to thank you personally. We'd also like to reassure you that we will always protect your privacy and respect how you prefer to hear from us and about our progress.

# **Information for Solicitors and Executors**

### **Deductible Gift Recipient Status**

The Garvan Institute of Medical Research (ABN 62 330 391 937) holds Deductible Gift Recipient (DGR) Status Item 1 and is fully Tax Exempt. As the Fundraising and Marketing division of the Garvan Institute, the Garvan Research Foundation (ABN 91 042 722 738) also holds Deductible Gift Recipient (DGR) Status Item 2 and is fully Tax Exempt.

## Capital Gains Tax on estate assets & transfer of shares 'in specie'

As Garvan Institute of Medical Research is fully Tax Exempt, the transfer of all Capital Gains Tax assets such as real estate or shares to Garvan will result in significantly reduced tax liability, rather than pre-selling those assets by executors and transferring the sale proceeds.

